Loading organizations...
683 Capital Management operates as a New York-based hedge fund, specializing in an investment strategy grounded in extensive fundamental research. The firm applies a disciplined analytical framework to identify compelling opportunities across diverse markets. Its methodology emphasizes a thorough understanding of company fundamentals and economic trends, aiming to construct robust portfolios.
The firm was established in May 2006 by founder Ari Zweiman. Zweiman's insight for launching 683 Capital Management stemmed from a conviction that a meticulous, research-driven process could effectively uncover undervalued assets and generate consistent returns. His background underpins the firm’s commitment to detailed due diligence and sustained value.
Serving a discerning client base, 683 Capital Management is dedicated to delivering long-term risk-adjusted returns through actively managed portfolios. The firm’s vision centers on achieving capital appreciation for its investors by continuously refining its strategic, fundamentals-driven methodology and adapting to evolving market landscapes.
683 Capital Management has 2 tracked investments across 2 companies. The latest tracked deal is $135.0M Series C in Amylyx Pharmaceuticals in July 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 20, 2021 | Amylyx Pharmaceuticals | $135.0M Series C | Viking Global Investors | Belinda Termeer, Bain Capital Life Sciences, Falcon Edge Capital, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Woodline Partners |
| Jun 23, 2021 | Tvardi Therapeutics | $74.0M Series B | 683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie Mcnab | Sporos Bioventures |